blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3512544

EP3512544 - PEPTIDE COMPOUNDS AND THERAPEUTIC USES THEREOF [Right-click to bookmark this link]
Former [2019/30]NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF
[2020/21]
StatusNo opposition filed within time limit
Status updated on  03.09.2021
Database last updated on 19.07.2024
FormerThe patent has been granted
Status updated on  25.09.2020
FormerGrant of patent is intended
Status updated on  29.04.2020
FormerRequest for examination was made
Status updated on  21.06.2019
FormerThe international publication has been made
Status updated on  24.03.2018
Formerunknown
Status updated on  02.10.2017
Most recent event   Tooltip03.05.2024Lapse of the patent in a contracting state
New state(s): MK		published on 05.06.2024  [2024/23]
Applicant(s)For all designated states
Centauri Therapeutics Limited
1st Floor Thavies Inn House
3-4 Holborn Circus
London EC1N 2HA / GB
[2019/30]
Inventor(s)01 / GLOSSOP, Melanie
c/o Centauri Therapeutics Limited
Discovery Park
Sandwich Kent CT13 7ND / GB
02 / WATSON, Christine
c/o Centauri Therapeutics Limited
Discovery Park
Sandwich Kent CT13 7ND / GB
03 / WESTBY, Michael
c/o Centauri Therapeutics Limited
Discovery Park
Sandwich Kent CT13 7ND / GB
 [2019/30]
Representative(s)Gibson, Mark, et al
Sagittarius IP
Marlow International
Parkway
Marlow SL7 1YL / GB
[2019/30]
Application number, filing date17771531.513.09.2017
[2019/30]
WO2017GB52699
Priority number, dateGB2016001556013.09.2016         Original published format: GB 201615560
GB2017000707604.05.2017         Original published format: GB 201707076
[2019/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018051085
Date:22.03.2018
Language:EN
[2018/12]
Type: A1 Application with search report 
No.:EP3512544
Date:24.07.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 22.03.2018 takes the place of the publication of the European patent application.
[2019/30]
Type: B1 Patent specification 
No.:EP3512544
Date:28.10.2020
Language:EN
[2020/44]
Search report(s)International search report - published on:EP22.03.2018
ClassificationIPC:A61K39/385, A61K47/54, A61K47/64, A61P31/00, A61K47/61, C07K7/62
[2020/21]
CPC:
C07K7/62 (EP,IL,KR,US); A61K47/61 (EP,IL,KR,US); A61K47/646 (EP,IL,KR,US);
A61P31/00 (EP,IL,US); Y02A50/30 (EP)
Former IPC [2019/30]A61K39/385, A61K47/54, A61K47/64
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/30]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:PEPTIDVERBINDUNGEN UND THERAPEUTISCHE VERWENDUNGEN DAVON[2020/21]
English:PEPTIDE COMPOUNDS AND THERAPEUTIC USES THEREOF[2020/21]
French:COMPOSÉS PEPTIDIQUES ET LEURS UTILISATIONS THÉRAPEUTIQUES[2020/21]
Former [2019/30]NEUARTIGE VERBINDUNGEN UND THERAPEUTISCHE VERWENDUNGEN DAVON
Former [2019/30]NOVEL COMPOUNDS AND THERAPEUTIC USES THEREOF
Former [2019/30]NOUVEAUX COMPOSÉS ET LEURS UTILISATIONS THÉRAPEUTIQUES
Entry into regional phase08.04.2019National basic fee paid 
08.04.2019Designation fee(s) paid 
08.04.2019Examination fee paid 
Examination procedure08.04.2019Examination requested  [2019/30]
08.04.2019Date on which the examining division has become responsible
17.10.2019Amendment by applicant (claims and/or description)
30.04.2020Communication of intention to grant the patent
07.09.2020Fee for grant paid
07.09.2020Fee for publishing/printing paid
07.09.2020Receipt of the translation of the claim(s)
Opposition(s)29.07.2021No opposition filed within time limit [2021/40]
Fees paidRenewal fee
23.09.2019Renewal fee patent year 03
21.09.2020Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU13.09.2017
AL28.10.2020
AT28.10.2020
CY28.10.2020
CZ28.10.2020
EE28.10.2020
HR28.10.2020
LT28.10.2020
LV28.10.2020
MC28.10.2020
MK28.10.2020
PL28.10.2020
RO28.10.2020
RS28.10.2020
SI28.10.2020
SK28.10.2020
SM28.10.2020
BG28.01.2021
NO28.01.2021
GR29.01.2021
IS28.02.2021
PT01.03.2021
[2024/23]
Former [2023/33]HU13.09.2017
AL28.10.2020
AT28.10.2020
CY28.10.2020
CZ28.10.2020
EE28.10.2020
HR28.10.2020
LT28.10.2020
LV28.10.2020
MC28.10.2020
PL28.10.2020
RO28.10.2020
RS28.10.2020
SI28.10.2020
SK28.10.2020
SM28.10.2020
BG28.01.2021
NO28.01.2021
GR29.01.2021
IS28.02.2021
PT01.03.2021
Former [2023/30]AL28.10.2020
AT28.10.2020
CY28.10.2020
CZ28.10.2020
EE28.10.2020
HR28.10.2020
LT28.10.2020
LV28.10.2020
MC28.10.2020
PL28.10.2020
RO28.10.2020
RS28.10.2020
SI28.10.2020
SK28.10.2020
SM28.10.2020
BG28.01.2021
NO28.01.2021
GR29.01.2021
IS28.02.2021
PT01.03.2021
Former [2022/25]AL28.10.2020
AT28.10.2020
CZ28.10.2020
EE28.10.2020
HR28.10.2020
LT28.10.2020
LV28.10.2020
MC28.10.2020
PL28.10.2020
RO28.10.2020
RS28.10.2020
SI28.10.2020
SK28.10.2020
SM28.10.2020
BG28.01.2021
NO28.01.2021
GR29.01.2021
IS28.02.2021
PT01.03.2021
Former [2022/23]AL28.10.2020
AT28.10.2020
CZ28.10.2020
EE28.10.2020
HR28.10.2020
LT28.10.2020
LV28.10.2020
PL28.10.2020
RO28.10.2020
RS28.10.2020
SI28.10.2020
SK28.10.2020
SM28.10.2020
BG28.01.2021
NO28.01.2021
GR29.01.2021
IS28.02.2021
PT01.03.2021
Former [2022/10]AL28.10.2020
AT28.10.2020
CZ28.10.2020
EE28.10.2020
HR28.10.2020
LT28.10.2020
LV28.10.2020
PL28.10.2020
RO28.10.2020
RS28.10.2020
SI28.10.2020
SK28.10.2020
SM28.10.2020
BG28.01.2021
NO28.01.2021
GR29.01.2021
PT01.03.2021
Former [2021/50]AL28.10.2020
AT28.10.2020
CZ28.10.2020
EE28.10.2020
HR28.10.2020
LT28.10.2020
LV28.10.2020
PL28.10.2020
RO28.10.2020
RS28.10.2020
SI28.10.2020
SK28.10.2020
SM28.10.2020
BG28.01.2021
NO28.01.2021
GR29.01.2021
IS28.02.2021
PT01.03.2021
Former [2021/45]AL28.10.2020
AT28.10.2020
CZ28.10.2020
EE28.10.2020
HR28.10.2020
LT28.10.2020
LV28.10.2020
PL28.10.2020
RO28.10.2020
RS28.10.2020
SK28.10.2020
SM28.10.2020
BG28.01.2021
NO28.01.2021
GR29.01.2021
IS28.02.2021
PT01.03.2021
Former [2021/36]AT28.10.2020
CZ28.10.2020
EE28.10.2020
HR28.10.2020
LT28.10.2020
LV28.10.2020
PL28.10.2020
RO28.10.2020
RS28.10.2020
SK28.10.2020
SM28.10.2020
BG28.01.2021
NO28.01.2021
GR29.01.2021
IS28.02.2021
PT01.03.2021
Former [2021/35]AT28.10.2020
CZ28.10.2020
HR28.10.2020
LT28.10.2020
LV28.10.2020
PL28.10.2020
RO28.10.2020
RS28.10.2020
SK28.10.2020
SM28.10.2020
BG28.01.2021
NO28.01.2021
GR29.01.2021
IS28.02.2021
PT01.03.2021
Former [2021/33]AT28.10.2020
HR28.10.2020
LT28.10.2020
LV28.10.2020
PL28.10.2020
RS28.10.2020
SM28.10.2020
BG28.01.2021
NO28.01.2021
GR29.01.2021
IS28.02.2021
PT01.03.2021
Former [2021/32]AT28.10.2020
HR28.10.2020
LV28.10.2020
PL28.10.2020
RS28.10.2020
SM28.10.2020
BG28.01.2021
NO28.01.2021
GR29.01.2021
IS28.02.2021
PT01.03.2021
Former [2021/28]AT28.10.2020
HR28.10.2020
LV28.10.2020
PL28.10.2020
RS28.10.2020
BG28.01.2021
NO28.01.2021
GR29.01.2021
IS28.02.2021
PT01.03.2021
Former [2021/25]AT28.10.2020
LV28.10.2020
PL28.10.2020
RS28.10.2020
BG28.01.2021
NO28.01.2021
GR29.01.2021
IS28.02.2021
PT01.03.2021
Former [2021/23]AT28.10.2020
LV28.10.2020
RS28.10.2020
BG28.01.2021
NO28.01.2021
GR29.01.2021
PT01.03.2021
Former [2021/22]RS28.10.2020
NO28.01.2021
PT01.03.2021
Former [2021/21]PT01.03.2021
Cited inInternational search[A]US2004185054  (MULLIS KARY B [US]) [A] 1-27 * paragraphs [0119] , [0028] , [0029] , [0056]; example 2 *;
 [AP]WO2017060729  (CENTAURI THERAPEUTICS LTD [GB]) [AP] 1-27 * page 2, line 27 - page 3, line 26 *;
 [AP]WO2017060728  (AVVINITY THERAPEUTICS LTD [GB]) [AP] 1-27 * page 2, line 30 - page 3, line 26 *;
 [A]  - SASCHA A. KRISTIAN ET AL, "Retargeting pre-existing human antibodies to a bacterial pathogen with an alpha-Gal conjugated aptamer", JOURNAL OF MOLECULAR MEDICINE., DE, (20150505), vol. 93, no. 6, doi:10.1007/s00109-015-1280-4, ISSN 0946-2716, pages 619 - 631, XP055327406 [A] 1-27 * abstract * * page 623, column 2, line 11 - line 15 *

DOI:   http://dx.doi.org/10.1007/s00109-015-1280-4
 [A]  - LI JUN ET AL, "Bacteria targeted by human natural antibodies using alpha-Gal conjugated receptor-specific glycopolymers", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, (19990801), vol. 7, no. 8, doi:10.1016/S0968-0896(99)00099-1, ISSN 0968-0896, pages 1549 - 1558, XP002404043 [A] 1-27 * abstract *

DOI:   http://dx.doi.org/10.1016/S0968-0896(99)00099-1
 [A]  - KANNAN P. NAICKER ET AL, "Design and synthesis of alpha-Gal-conjugated peptide T20 as novel antiviral agent for HIV-immunotargeting", ORGANIC & BIOMOLECULAR CHEMISTRY, (20040301), vol. 2, no. 5, doi:10.1039/B313844E, ISSN 1477-0520, pages 660 - 664, XP055025921 [A] 1-27 * abstract *

DOI:   http://dx.doi.org/10.1039/B313844E
 [A]  - FERGUSON ELAINE L ET AL, "Dextrin-colistin conjugates as a model bioresponsive treatment for multidrug resistant bacterial infections.", MOLECULAR PHARMACEUTICS 01 DEC 2014, (20141201), vol. 11, no. 12, ISSN 1543-8392, pages 4437 - 4447, XP002775530 [A] 1-27 * abstract *

DOI:   http://dx.doi.org/10.1021/mp500584u
 [A]  - H. TSUBERY ET AL, "Neopeptide Antibiotics That Function as Opsonins and Membrane-Permeabilizing Agents for Gram-Negative Bacteria", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (20050801), vol. 49, no. 8, doi:10.1128/AAC.49.8.3122-3128.2005, ISSN 0066-4804, pages 3122 - 3128, XP055083865 [A] 1-27 * abstract *

DOI:   http://dx.doi.org/10.1128/AAC.49.8.3122-3128.2005
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.